Terui T, et al. - The effectiveness and safety of guselkumab, an anti–IL-23 monoclonal antibody, were assessed in Japanese patients with palmoplantar pustulosis (PPP). For the treatment of PPP, targeting IL-23 and its associated immune cascade with guselkumab could serve as a safe and useful therapeutic option.